Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661906 | 1.00 | HCAR2 (0.50) | HCAR2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL4439683 | 1.00 | HCAR2 (0.50) | HCAR2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL8940101 | 0.92 | LMNA (0.44) | HCAR2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL6665040 | 0.92 | LMNA (0.44) | HCAR2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL4439685 | 0.92 | LMNA (0.44) | HCAR2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL15794290 | 0.90 | HCAR2 (0.56) | HCAR2KDM4ETSHRTP53EGLN1 | |
| SCHEMBL15794287 | 0.90 | HCAR2 (0.56) | HCAR2KDM4ETSHRTP53EGLN1 | |
| Hexadecane SCHEMBL28028773 | 0.88 | HCAR2 (0.61) | HCAR2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL17172093 | 0.86 | LMNA (0.41) | HCAR2KDM4EDUSP3MEN1KMT2A | |
| Maleic Acid SCHEMBL28185920 | 0.86 | LMNA (0.41) | HCAR2KDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119235804-A | Carbamazepine pharmaceutical composition and preparation method and application thereof | 上海则正医药科技股份有限公司 | 2025-01-03 | — | — | CN | claimed |
| US-12090254-B2 | Composite tubular material prepared from extracellular matrix and synthetic polymer, and preparation method thereof | NANKAI UNIVERSITY (CN) | 2024-09-17 | — | — | US | claimed |
| US-20240238206-A1 | LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS | Midas Pharma GmbH (DE) | 2024-07-18 | — | — | US | claimed |
| CN-118055759-A | Miniature tablet containing losartan for pediatric use | 米达斯制药有限责任公司 | 2024-05-17 | — | — | CN | claimed |
| EP-4135668-B1 | SOLID ORAL DOSAGE FORM COMPRISING POMALIDOMIDE | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2024-04-17 | — | — | EP | claimed |
| EP-4333816-A1 | LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS | Midas Pharma GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| US-20240024539-A1 | COMPOSITE TUBULAR MATERIAL PREPARED FROM EXTRACELLULAR MATRIX AND SYNTHETIC POLYMER, AND PREPARATION METHOD THEREOF | UNIV NANKAI (CN) | 2024-01-25 | — | — | US | claimed |
| CN-116947642-A | Long-residence polyalcohol hair care raw material molecule and preparation and application thereof | 江南大学 | 2023-10-27 | — | — | CN | claimed |
| CN-113336929-B | Degradable photocrosslinking triblock copolymer and preparation method and application thereof | 中山大学 | 2023-07-11 | — | — | CN | claimed |
| WO-2023104096-A1 | POROUS MICROCARRIER AND PREPARATION METHOD THEREFOR | 中科睿极(深圳)医学科技有限公司 | 2023-06-15 | — | — | WO | claimed |
| EP-3429561-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION. | Midas Pharma GmbH (DE) | 2019-01-23 | — | — | EP | claimed |
| US-20180243283-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF THE INCORPORATION OF LENALIDOMIDE IN VARIOUS CRYSTALLINE MODIFICATIONS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2018-08-30 | — | — | US | claimed |
| US-9895325-B2 | Tablet composition comprising cinacalcet hydrochloride | SYNTHON B.V. (NL) | 2018-02-20 | — | — | US | claimed |
| WO-2017158094-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION. | K.H.S. PHARMA HOLDING GMBH (DE) | 2017-09-21 | — | — | WO | claimed |
| EP-3219309-A1 | FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION | K.H.S. Pharma Holding GmbH (DE) | 2017-09-20 | — | — | EP | claimed |
| WO-2017032870-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF THE INCORPORATION OF LENALIDOMIDE IN VARIOUS CRYSTALLINE MODIFICATIONS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2017-03-02 | — | — | WO | claimed |
| EP-3135275-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF THE INCORPORATION OF LENALIDOMIDE IN VARIOUS CRYSTALLINE MODIFICATIONS | Grindeks, A Joint Stock Company (LV) | 2017-03-01 | — | — | EP | claimed |
| EP-3002006-A1 | Pharmaceutical composition capable for the incorporation Febuxostat in the crystalline modifications F10, II, G and A | Bluepharma - Industria Farmacêutica, S.A. (PT) | 2016-04-06 | — | — | EP | claimed |
| WO-2014029953-A1 | HOT MELT EXTRUDED (HME) PHARMACEUTICAL COMPOSITION OF CINACALCET | CIPLA LIMITED (IN) | 2014-02-27 | — | — | WO | claimed |
| EP-0516141-B1 | Pharmaceutical controlled-release composition with bioadhesive properties | RECORDATI CHEM PHARM (CH) | 1996-08-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243283-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF THE INCORPORATION OF LENALIDOMIDE IN VARIOUS CRYSTALLINE MODIFICATIONS | RPL7, RPL26, PDCD2L | HCAR2 3609/4885KDM4E 1761/4885DUSP3 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.